Research graph
References from A CXCL10-enriched hepatic-risk phenotype reveals a cell-count paradox in severe COVID-19. Local targets link to admitted publications; unresolved targets remain external evidence.
Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases
10.3390/ijms23073636 · 2022 · External reference
Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: a systematic review and meta-analysis
10.1002/jmv.27297 · 2022 · External reference
Systemic inflammation index, disease severity, and mortality in patients with COVID-19: a systematic review and meta-analysis
10.3389/fimmu.2023.1212998 · 2023 · External reference
Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit
10.1186/cc9309 · 2010 · External reference
Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patients
10.1016/j.ajem.2016.10.055 · 2017 · External reference
Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis
10.1002/jmv.25819 · 2020 · External reference
The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study
10.1186/s13054-014-0731-6 · 2015 · External reference
Cirrhosis-associated immune dysfunction
10.1038/s41575-021-00520-7 · 2022 · External reference
10.1016/j.cgh.2009.02.021
10.1016/j.cgh.2009.02.021 · External reference
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
10.1002/hep.21178 · 2006 · External reference
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
Elevation of liver fibrosis index FIB-4 is associated with poor clinical outcomes in patients with COVID-19
10.1093/infdis/jiaa355 · 2020 · External reference
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
10.1136/gutjnl-2020-321611 · 2020 · External reference
An inflammatory cytokine signature predicts COVID-19 severity and survival
10.1038/s41591-020-1051-9 · 2020 · External reference
On behalf of the HLH across Speciality collaboration, UK, COVID-19: consider cytokine storm syndromes and immunosuppression
10.1016/s0140-6736(20)30628-0 · 2020 · External reference
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19
10.1126/sciimmunol.abd1554 · 2020 · External reference
Longitudinal analyses reveal immunological misfiring in severe COVID-19
10.1038/s41586-020-2588-y · 2020 · External reference
Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience
10.1111/liv.14583 · 2020 · External reference
Distinct cytokine profiles in severe COVID-19 and non-alcoholic fatty liver disease
2022 · External reference
TGF beta as a prognostic biomarker of COVID-19 severity in patients with NAFLD-A prospective case-control study
10.3390/microorganisms11061571 · 2023 · External reference
COVID-19 and pulmonary thrombosis-an unresolved clinical puzzle: a single-center cohort study
10.3390/jcm11237049 · 2022 · External reference
Association of nonalcoholic fatty liver disease with COVID-19 severity and pulmonary thrombosis: CovidFAT, a prospective, observational cohort study
10.1093/ofid/ofac073 · 2022 · External reference
The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients
10.1016/j.intimp.2020.106504 · 2020 · External reference
The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved
10.1016/j.cytogfr.2020.12.005 · 2021 · External reference
CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications
2011 · External reference
What is currently known about the role of CXCL10 in SARS-CoV-2 infection?
10.3390/ijms23073673 · 2022 · External reference
Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. cohort
10.1002/hep.31404 · 2020 · External reference
Comparison of liver function test- and inflammation-based prognostic scores for coronavirus disease 2019: a single center study
10.1097/meg.0000000000002446 · 2022 · External reference
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury spectrum study)
10.1007/s12072-020-10072-8 · 2020 · External reference
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
10.1016/j.jaci.2020.08.031 · 2021 · External reference
CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients
2020 · External reference
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study
10.1186/s10020-021-00390-4 · 2021 · External reference
Roles for chemokines in liver disease
10.1053/j.gastro.2014.06.043 · 2014 · External reference
Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases
10.1111/j.1478-3231.2011.02504.x · 2011 · External reference
Compartmentalized regulation of pulmonary and systemic inflammation in critical COVID-19 patients
10.3390/v15081704 · 2023 · External reference
10.1016/j.cell.2020.08.001
10.1016/j.cell.2020.08.001 · External reference
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies
10.3389/fimmu.2025.1682049 · 2025 · External reference
